

Recombinant human Fab fragments neutralize human t
vitro.

Proceedings of the National Academy of Sciences of the United
89, 9339-9343

DOI: 10.1073/pnas.89.19.9339

Citation Report

#	ARTICLE	IF	CITATIONS
1	A binary plasmid system for shuffling combinatorial antibody libraries.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10026-10030.	7.1	79
2	Antibodies from libraries. Nature, 1992, 359, 782-783.	27.8	38
3	Immunotherapeutic strategies in the treatment of HIV infection and AIDS. Current Opinion in Immunology, 1993, 5, 600-607.	5.5	8
4	Recent advances in phage display. Current Opinion in Biotechnology, 1993, 4, 526-530.	6.6	65
5	The HIV gp120-CD4 interaction: A target for pharmacological or immunological intervention?. Journal of Computer - Aided Molecular Design, 1993, 1, 235-250.	1.0	37
6	Monoclonal antibodies from combinatorial libraries. Accounts of Chemical Research, 1993, 26, 405-411.	15.6	39
7	Selection of human anti-hapten antibodies from semisynthetic libraries. Gene, 1993, 137, 57-62.	2.2	65
8	Isolation and characterization of nucleic acid-binding antibody fragments from autoimmune mice-derived bacteriophage display libraries. Gene, 1993, 137, 77-83.	2.2	25
9	Combinatorial Libraries. International Reviews of Immunology, 1993, 10, 153-163.	3.3	5
10	Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 4141-4145.	7.1	172
11	High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10003-10007.	7.1	96
12	Isolation of high affinity human antibodies directly from large synthetic repertoires.. EMBO Journal, 1994, 13, 3245-3260.	7.8	867
13	Expression and characterization of recombinant anti-Rh(D) antibodies on filamentous phage: a model system for isolating human red blood cell antibodies by repertoire cloning. Blood, 1994, 83, 2334-2344.	1.4	51
14	Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 1386-1390.	7.1	127
15	Human Antibodies from Combinatorial Libraries. Advances in Immunology, 1994, 57, 191-280.	2.2	192
16	Recombinant thyroid peroxidase-specific autoantibodies. I. How diverse is the pool of heavy and light chains in immunoglobulin gene libraries constructed from thyroid tissue-infiltrating plasma cells.. Endocrinology, 1994, 135, 16-24.	2.8	16
17	Analysis of B Cell Repertoire Specific to the Neutralizing Epitopes of Glycoprotein 120 in HIV-Infected Individuals. AIDS Research and Human Retroviruses, 1994, 10, 1629-1637.	1.1	7
18	Specific Binding of Antibodies to DNA through Combinatorial Antibody Libraries. Angewandte Chemie International Edition in English, 1994, 33, 1827-1829.	4.4	5

#	ARTICLE	IF	CITATIONS
19	Spezifische Bindung von Antikörpern an DNA mit kombinatorischen Antikörper-Bibliotheken. <i>Angewandte Chemie</i> , 1994, 106, 1911-1914.	2.0	4
20	Filamentous phage display. <i>Fibrinolysis</i> , 1994, 8, 245-252.	0.5	10
21	Surface display of antibodies. <i>Biotechnology Advances</i> , 1994, 12, 539-555.	11.7	21
22	Human Monoclonal Antibodies: Recent Achievements. <i>Hospital Practice (1995)</i> , 1994, 29, 111-122.	1.0	6
23	In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 3809-3813.	7.1	228
24	An Improved Phage Display Antibody Cloning System Using Newly Designed PCR Primers Optimized for Pfu DNA Polymerase. <i>Journal of Biochemistry</i> , 1995, 117, 1218-1227.	1.7	25
25	Polyclonal Preparations of Anti-Tetanus Toxoid Antibodies Derived from a Combinatorial Library Confer Protection. <i>Nature Biotechnology</i> , 1995, 13, 683-685.	17.5	3
26	Combinatorial libraries: new insights into human organ-specific autoantibodies. <i>Trends in Immunology</i> , 1995, 16, 43-49.	7.5	49
27	A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. <i>Blood</i> , 1995, 86, 4430-4436.	1.4	92
28	Two-Phase Approach for the Expression of High-Affinity Human Anti-Human Immunodeficiency Virus Immunoglobulin Fab Domains in <i>Escherichia coli</i> . <i>Hybridoma</i> , 1995, 14, 9-18.	0.6	8
29	Peptide and protein display on the surface of filamentous bacteriophage. <i>Biotechnology Annual Review</i> , 1995, 1, 149-183.	2.1	38
30	Human monoclonal Fab fragments specific for viral antigens from combinatorial IgA libraries. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1995, 1, 21-28.	2.4	15
31	A human pancreatic secretory trypsin inhibitor presenting a hypervariable highly constrained epitope via monovalent phagemid display. <i>Gene</i> , 1995, 164, 243-250.	2.2	46
32	CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range. <i>Journal of Molecular Biology</i> , 1995, 254, 392-403.	4.2	355
33	Epitope mapping, V-region DNA sequence, and neutralizing Fab fragments of two monoclonal antibodies against the HIV-1 V3 loop. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1996, 2, 11-20.	2.4	2
34	Antibodies against HIV-1 from Phage Display Libraries: Mapping of an Immune Response and Progress towards Antiviral Immunotherapy. <i>Chemical Immunology and Allergy</i> , 1996, 65, 18-56.	1.7	4
35	Human antibodies from phage libraries: neutralizing activity against human immunodeficiency virus type 1 equally improved after expression as Fab and IgG in mammalian cells. <i>European Journal of Immunology</i> , 1996, 26, 3029-3034.	2.9	20
36	In vitro immunization of naive human B cells yields high affinity immunoglobulin G antibodies as illustrated by phage display. <i>Immunology</i> , 1996, 89, 1-7.	4.4	37

#	ARTICLE	IF	CITATIONS
37	Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library. <i>Nature Biotechnology</i> , 1996, 14, 309-314.	17.5	956
38	Human Antibody Responses to HIV Type 1 Glycoprotein 41 Cloned in Phage Display Libraries Suggest Three Major Epitopes Are Recognized and Give Evidence for Conserved Antibody Motifs in Antigen Binding. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 911-924.	1.1	81
39	Humoral Immune Response to Immunocomplexed HIV Envelope Glycoprotein 120. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 901-909.	1.1	28
40	Recombinant Human Monoclonal Antibody IgG1b12 Neutralizes Diverse Human Immunodeficiency Virus Type 1 Primary Isolates. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 575-582.	1.1	82
41	Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Lineâ€“adapted HIV-1 Neutralization. <i>Journal of Experimental Medicine</i> , 1997, 186, 1287-1298.	8.5	124
42	Summary of Antibody Workshop: The Role of Humoral Immunity in the Treatment and Prevention of Emerging and Extant Infectious Diseases. <i>Journal of Infectious Diseases</i> , 1997, 176, 549-559.	4.0	54
43	High affinity human antibodies by phage display. <i>Human Antibodies</i> , 1997, 8, 155-168.	1.5	23
44	A vaccine for HIV type 1: The antibody perspective. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 10018-10023.	7.1	214
45	Production of a Human Antibody Library in the Phage-Display Vector pSEX81. , 1998, 13, 593-604.		7
46	Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries 1 Edited by F. E. Cohen. <i>Journal of Molecular Biology</i> , 1997, 267, 684-695.	4.2	57
47	Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinuous Epitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 1549-1559.	1.1	38
48	Biologically active human anti-crotoxin scFv isolated from a semi-synthetic phage library. <i>Immunotechnology: an International Journal of Immunological Engineering</i> , 1997, 3, 117-125.	2.4	21
49	Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 1521-1530.	3.2	566
50	A Human IgG1 (b12) Specific for the CD4 Binding Site of HIV-1 Neutralizes by Inhibiting the Virus Fusion Entry Process, but b12 Fab Neutralizes by Inhibiting a Postfusion Event. <i>Virology</i> , 1997, 233, 313-326.	2.4	56
51	A recombinant single chain antibody neutralizes coronavirus infectivity but only slightly delays lethal infection of mice. <i>European Journal of Immunology</i> , 1997, 27, 3447-3455.	2.9	14
52	Human monoclonal anti-HCMV neutralizing antibody from phage display libraries. <i>Journal of Virological Methods</i> , 1998, 74, 89-98.	2.1	30
53	Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant fab fragments. <i>Hepatology</i> , 1998, 28, 810-814.	7.3	51
54	Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. <i>Aids</i> , 1998, 12, 1413-1418.	2.2	6

#	ARTICLE	IF	CITATIONS
55	Generation of Recombinant Antibodies. <i>Molecular Biotechnology</i> , 1999, 12, 173-202.	2.4	64
56	A bidirectional phage display vector for the selection and mass transfer of polyclonal antibody libraries. <i>Journal of Immunological Methods</i> , 1999, 222, 45-57.	1.4	13
57	Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. <i>European Journal of Immunology</i> , 1999, 29, 1901-1911.	2.9	65
58	<i>Entamoeba histolytica</i> : Bacterial Expression of a Human Monoclonal Antibody Which Inhibits in Vitro Adherence of Trophozoites. <i>Experimental Parasitology</i> , 2000, 96, 52-56.	1.2	8
59	The use of Envelope for HIV therapeutics: from vaccines to co-receptors. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 423-437.	1.0	1
60	A Retro-Inverso Miniantibody with Anti-HIV Activity. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 59-65.	1.1	12
61	Passive Immunization Against Dental Caries and Periodontal Disease: Development of Recombinant and Human Monoclonal Antibodies. <i>Critical Reviews in Oral Biology and Medicine</i> , 2000, 11, 140-158.	4.4	64
62	Recognition Properties of V3-Specific Antibodies to V3 Loop Peptides Derived from HIV-1 gp120 Presented in Multiple Conformations. <i>Biochemistry</i> , 2000, 39, 10866-10876.	2.5	6
63	A novel expression vector for production of epitope-tagged recombinant Fab fragments in bacteria. <i>Human Antibodies</i> , 2001, 10, 149-154.	1.5	3
64	Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs. <i>Virology</i> , 2001, 288, 29-35.	2.4	38
65	Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 664-672.	3.2	89
66	From catalytic asymmetric synthesis to the transcriptional regulation of genes: In vivo and in vitro evolution of proteins. <i>Advances in Protein Chemistry</i> , 2001, 55, 317-366.	4.4	7
67	Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41. <i>Journal of Virology</i> , 2001, 75, 10892-10905.	3.4	734
69	Development of a Safe and Rapid Neutralization Assay Using Murine Leukemia Virus Pseudotyped with HIV Type 1 Envelope Glycoprotein Lacking the Cytoplasmic Domain. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1715-1724.	1.1	26
70	Generation and Screening of a Modular Human scFv Expression Library from Multiple Donors. , 2003, 207, 103-122.		0
71	Recombinant antibody Fab against the hypervariable region 1 of hepatitis C virus blocks the virus adsorption to susceptible cells in vitro. <i>Antiviral Research</i> , 2002, 56, 51-59.	4.1	6
72	Immunogenicity and Ability of Variable Loop-Deleted Human Immunodeficiency Virus Type 1 Envelope Glycoproteins to Elicit Neutralizing Antibodies. <i>Virology</i> , 2003, 305, 124-137.	2.4	57
73	A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny. <i>Virology</i> , 2003, 315, 362-372.	2.4	23

#	ARTICLE	IF	CITATIONS
74	Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2003, 77, 642-658.	3.4	237
75	Envelope Variants from Women Recently Infected with Clade A Human Immunodeficiency Virus Type 1 Confer Distinct Phenotypes That Are Discerned by Competition and Neutralization Experiments. <i>Journal of Virology</i> , 2003, 77, 8448-8461.	3.4	8
76	Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design. <i>Journal of Virology</i> , 2003, 77, 5889-5901.	3.4	126
77	Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. <i>Journal of General Virology</i> , 2003, 84, 353-360.	2.9	47
78	A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12. <i>Journal of Virology</i> , 2003, 77, 6965-6978.	3.4	67
79	Isolation of Human Monoclonal Antibodies That Neutralize Human Rotavirus. <i>Journal of Virology</i> , 2004, 78, 3325-3332.	3.4	39
80	HIV-1-Infected Patients with Envelope-Specific Lymphoproliferation or Long-Term Nonprogression Lack Antibodies Suppressing Glycoprotein 120 Antigen Presentation. <i>Journal of Infectious Diseases</i> , 2004, 189, 852-861.	4.0	9
81	Identifying epitopes of HIV-1 that induce protective antibodies. <i>Nature Reviews Immunology</i> , 2004, 4, 199-210.	22.7	292
82	Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. <i>Virology</i> , 2004, 327, 242-248.	2.4	28
83	Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. <i>Journal of Virology</i> , 2004, 78, 13232-13252.	3.4	665
84	Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection. <i>Vaccine</i> , 2004, 22, 383-397.	3.8	2
85	Construction and characterization of a Fab recombinant protein for Japanese encephalitis virus neutralization. <i>Vaccine</i> , 2004, 23, 163-171.	3.8	10
86	HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. <i>Aids</i> , 2004, 18, 1769-1779.	2.2	57
87	Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale. <i>Veterinary Journal</i> , 2005, 170, 193-211.	1.7	28
88	An antibody specific for the C-terminal tail of the gp41 transmembrane protein of human immunodeficiency virus type 1 mediates post-attachment neutralization, probably through inhibition of virus-cell fusion. <i>Journal of General Virology</i> , 2005, 86, 1499-1507.	2.9	14
89	Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. <i>Journal of Virology</i> , 2005, 79, 8454-8469.	3.4	76
90	Role of Neutralizing Antibodies in Protective Immunity Against HIV. <i>Hum Vaccin</i> , 2005, 1, 45-60.	2.4	40
91	Comparing Antigenicity and Immunogenicity of Engineered gp120. <i>Journal of Virology</i> , 2005, 79, 12148-12163.	3.4	96

#	ARTICLE	IF	CITATIONS
92	GP120: Target for Neutralizing HIV-1 Antibodies. Annual Review of Immunology, 2006, 24, 739-769.	21.8	404
93	Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnology and Applied Biochemistry, 2006, 45, 93.	3.1	26
94	Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Virology, 2006, 352, 131-144.	2.4	23
95	Citrate-mediated disaggregation of rotavirus particles in RotaTeq® vaccine. Antiviral Research, 2006, 69, 107-115.	4.1	7
96	Manufacturing Immunity to Disease in a Test Tube: The Magic Bullet Realized. Angewandte Chemie - International Edition, 2006, 45, 8106-8125.	13.8	71
98	Human Neutralizing Fab Molecules against Severe Acute Respiratory Syndrome Coronavirus Generated by Phage Display. Vaccine Journal, 2006, 13, 953-957.	3.1	20
99	Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120. FASEB Journal, 2006, 20, 1762-1774.	0.5	34
100	Production of High-Affinity Human Monoclonal Antibody Fab Fragments to the 19-Kilodalton C-Terminal Merozoite Surface Protein 1 of Plasmodium falciparum. Infection and Immunity, 2007, 75, 3614-3620.	2.2	15
101	Passive Immunization as Tool to Identify Protective HIV-1 Env Epitopes. Current HIV Research, 2007, 5, 642-655.	0.5	34
102	Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. Journal of Virology, 2007, 81, 6548-6562.	3.4	181
103	HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. Aids, 2007, 21, 693-702.	2.2	66
104	Designing Immunogens to Elicit Broadly Neutralizing Antibodies to the HIV-1 Envelope Glycoprotein. Current HIV Research, 2007, 5, 514-541.	0.5	29
105	Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine, 2007, 25, 5102-5114.	3.8	54
106	Synthetic Mimetics of the CD4 Binding Site of HIV-1 gp120 for the Design of Immunogens. Angewandte Chemie - International Edition, 2007, 46, 1253-1255.	13.8	32
108	Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity. Journal of Medical Virology, 2007, 79, 852-862.	5.0	17
109	Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology, 2007, 364, 441-453.	2.4	65
110	Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology, 2008, 370, 246-254.	2.4	37
111	Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmunity Reviews, 2008, 7, 468-472.	5.8	33

#	ARTICLE	IF	CITATIONS
112	Deceptive imprinting and immune refocusing in vaccine design. <i>Vaccine</i> , 2008, 26, 6189-6199.	3.8	92
113	Focused Dampening of Antibody Response to the Immunodominant Variable Loops by Engineered Soluble gp140. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 301-314.	1.1	36
114	Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein. <i>Journal of Virology</i> , 2008, 82, 1047-1052.	3.4	119
115	Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120. <i>Journal of Virology</i> , 2008, 82, 12069-12081.	3.4	103
116	Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses. <i>Journal of Virology</i> , 2008, 82, 638-651.	3.4	154
117	Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41. <i>PLoS Medicine</i> , 2008, 5, e9.	8.4	85
118	Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment. <i>Journal of Virology</i> , 2009, 83, 10892-10907.	3.4	86
119	Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7385-7390.	7.1	146
120	Characterization of <i>Entamoeba histolytica</i> Intermediate Subunit Lectin-Specific Human Monoclonal Antibodies Generated in Transgenic Mice Expressing Human Immunoglobulin Loci. <i>Infection and Immunity</i> , 2009, 77, 549-556.	2.2	15
121	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. <i>Journal of Virology</i> , 2009, 83, 5077-5086.	3.4	43
122	Neutralization-Sensitive R5-Tropic Simian-Human Immunodeficiency Virus SHIV-2873Nip, Which Carries <i>env</i> Isolated from an Infant with a Recent HIV Clade C Infection. <i>Journal of Virology</i> , 2009, 83, 1422-1432.	3.4	37
123	Generation and Characterization of High Affinity Humanized Fab Against Hepatitis B Surface Antigen. <i>Molecular Biotechnology</i> , 2009, 43, 29-40.	2.4	4
124	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. <i>Nature Medicine</i> , 2009, 15, 866-870.	30.7	390
126	HIV sensitivity to neutralization is determined by target and virus producer cell properties. <i>Aids</i> , 2009, 23, 1659-1667.	2.2	47
127	Divergent effects of cell environment on HIV entry inhibitor activity. <i>Aids</i> , 2009, 23, 1319-1327.	2.2	28
128	Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances. <i>Current Pharmaceutical Design</i> , 2010, 16, 3754-3766.	1.9	8
129	Antibody Epitope Exposure and Neutralization of HIV-1. <i>Current Pharmaceutical Design</i> , 2010, 16, 3729-3743.	1.9	17
130	Biomarker discovery and clinical proteomics. <i>TrAC - Trends in Analytical Chemistry</i> , 2010, 29, 128-140.	11.4	78

#	ARTICLE	IF	CITATIONS
131	Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion. <i>Journal of Virology</i> , 2010, 84, 8132-8140.	3.4	86
132	Design of a Non-glycosylated Outer Domain-derived HIV-1 gp120 Immunogen That Binds to CD4 and Induces Neutralizing Antibodies. <i>Journal of Biological Chemistry</i> , 2010, 285, 27100-27110.	3.4	33
133	Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. <i>Journal of Experimental Medicine</i> , 2010, 207, 1995-2002.	8.5	62
134	Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. <i>Expert Review of Vaccines</i> , 2010, 9, 645-664.	4.4	37
135	Accessing the human repertoire for broadly neutralizing HIV antibodies. <i>MAbs</i> , 2010, 2, 157-164.	5.2	24
136	Global structure of HIV-1 neutralizing antibody IgG1 b12 is asymmetric. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 947-951.	2.1	20
137	Production of Antibody Fab Fragments in <i>Escherichia coli</i> . <i>Cell Engineering</i> , 2011, , 165-178.	0.4	0
138	Functional expression of chimeric Fab of an anti-CD40L mAb: Vector design and culture condition optimization. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 52-59.	5.6	2
139	Antibody Expression and Production. <i>Cell Engineering</i> , 2011, , .	0.4	4
140	Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. <i>Vaccine</i> , 2011, 29, 4903-4912.	3.8	38
141	Parallel Processing of Complex Biomolecular Information: Combining Experimental and Computational Approaches. , 2011, , .		0
142	Increased Sensitivity to Broadly Neutralizing Antibodies of End-Stage Disease R5 HIV-1 Correlates with Evolution in Env Glycosylation and Charge. <i>PLoS ONE</i> , 2011, 6, e20135.	2.5	16
143	Nanobodies®: New ammunition to battle viruses. <i>Antiviral Research</i> , 2011, 92, 389-407.	4.1	123
144	Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion. <i>Journal of Infectious Diseases</i> , 2011, 204, 1692-1701.	4.0	54
145	Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. <i>Retrovirology</i> , 2011, 8, 16.	2.0	72
146	Mutagenesis of tyrosine and di-leucine motifs in the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. <i>Retrovirology</i> , 2011, 8, 37.	2.0	45
147	MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. <i>Journal of Experimental Medicine</i> , 2011, 208, 439-454.	8.5	95
148	Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site. <i>Journal of Virology</i> , 2011, 85, 9039-9050.	3.4	49

#	ARTICLE	IF	CITATIONS
149	Genetic and Neutralization Sensitivity of Diverse HIV-1 env Clones from Chronically Infected Patients in China. <i>Journal of Biological Chemistry</i> , 2011, 286, 14531-14541.	3.4	51
150	Phenotypic and Immunologic Comparison of Clade B Transmitted/Founder and Chronic HIV-1 Envelope Glycoproteins. <i>Journal of Virology</i> , 2011, 85, 8514-8527.	3.4	110
151	Generation of a Neutralizing Human Monoclonal Antibody Fab Fragment to Surface Antigen 1 of <i>Toxoplasma gondii</i> Tachyzoites. <i>Infection and Immunity</i> , 2011, 79, 512-517.	2.2	16
152	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. <i>Journal of Virology</i> , 2011, 85, 5804-5813.	3.4	37
153	Phages and HIV-1: From Display to Interplay. <i>International Journal of Molecular Sciences</i> , 2012, 13, 4727-4794.	4.1	17
154	Transmembrane Domain Membrane Proximal External Region but Not Surface Unit "Directed Broadly Neutralizing HIV-1 Antibodies Can Restrict Dendritic Cell-Mediated HIV-1 Trans-infection. <i>Journal of Infectious Diseases</i> , 2012, 205, 1248-1257.	4.0	38
155	HIV-Specific Antibodies Capable of ADCC Are Common in Breastmilk and Are Associated with Reduced Risk of Transmission in Women with High Viral Loads. <i>PLoS Pathogens</i> , 2012, 8, e1002739.	4.7	224
156	Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies. <i>PLoS Pathogens</i> , 2012, 8, e1002634.	4.7	189
157	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. <i>Journal of Virology</i> , 2012, 86, 4394-4403.	3.4	109
158	HIV gp120 H375 Is Unique to HIV-1 Subtype CRF01_AE and Confers Strong Resistance to the Entry Inhibitor BMS-599793, a Candidate Microbicide Drug. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4257-4267.	3.2	30
159	MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. <i>Retrovirology</i> , 2012, 9, 36.	2.0	17
160	Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. <i>Immunological Reviews</i> , 2012, 250, 180-198.	6.0	84
161	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. <i>Journal of Virology</i> , 2012, 86, 7588-7595.	3.4	123
162	Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses. <i>Science</i> , 2012, 337, 183-186.	12.6	394
163	Neutralization sensitivity of HIV-1 subtype B clinical isolates from former plasma donors in China. <i>Virology Journal</i> , 2013, 10, 10.	3.4	15
164	Closing the door to human immunodeficiency virus. <i>Protein and Cell</i> , 2013, 4, 86-102.	11.0	13
165	Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. <i>Retrovirology</i> , 2013, 10, 147.	2.0	4
167	Anti-Idiotypic Monobodies Derived from a Fibronectin Scaffold. <i>Biochemistry</i> , 2013, 52, 1802-1813.	2.5	10

#	ARTICLE	IF	CITATIONS
168	Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs. PLoS Pathogens, 2013, 9, e1003106.	4.7	172
169	The Griffithsin Dimer Is Required for High-Potency Inhibition of HIV-1: Evidence for Manipulation of the Structure of gp120 as Part of the Griffithsin Dimer Mechanism. Antimicrobial Agents and Chemotherapy, 2013, 57, 3976-3989.	3.2	40
170	Conformation-Dependent Recognition of HIV gp120 by Designed Ankyrin Repeat Proteins Provides Access to Novel HIV Entry Inhibitors. Journal of Virology, 2013, 87, 5868-5881.	3.4	34
171	Isolate-Specific Differences in the Conformational Dynamics and Antigenicity of HIV-1 gp120. Journal of Virology, 2013, 87, 10855-10873.	3.4	29
172	Selection of Intracellular Single-Domain Antibodies Targeting the HIV-1 Vpr Protein by Cytoplasmic Yeast Two-Hybrid System. PLoS ONE, 2014, 9, e113729.	2.5	14
173	Different Approaches for Obtaining Antibodies from Human B Cells. Current Drug Discovery Technologies, 2014, 11, 41-47.	1.2	6
174	Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12. Virologica Sinica, 2014, 29, 299-307.	3.0	5
175	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17624-17629.	7.1	324
176	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity, 2014, 40, 657-668.	14.3	342
177	Profiling the IgOme: Meeting the challenge. FEBS Letters, 2014, 588, 318-325.	2.8	14
178	Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. Virology, 2014, 462-463, 363-376.	2.4	19
179	Atomic force microscopy fishing of GP120 on immobilized aptamers and its mass spectrometry identification. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2014, 8, 115-124.	0.4	5
180	Immunogen design for HIV-1 and influenza. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1891-1906.	2.3	23
181	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Naïve Chronically HIV-1 Infected Individuals. PLoS ONE, 2015, 10, e0120648.	2.5	5
182	Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. PLoS ONE, 2015, 10, e0125575.	2.5	13
183	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Nature Communications, 2015, 6, 6144.	12.8	130
184	CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants. Journal of General Virology, 2015, 96, 1899-1905.	2.9	10
185	Highly reproductive Escherichia coli cells with no specific assignment to the UAG codon. Scientific Reports, 2015, 5, 9699.	3.3	126

#	ARTICLE	IF	CITATIONS
186	Antibody responses to envelope glycoproteins in HIV-1 infection. <i>Nature Immunology</i> , 2015, 16, 571-576.	14.5	364
187	The Orientation of HIV-1 gp120 Binding to the CD4 Receptor Differentially Modulates CD4+ T Cell Activation. <i>Journal of Immunology</i> , 2015, 194, 637-649.	0.8	9
188	Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection. <i>Vaccines</i> , 2016, 4, 2.	4.4	17
189	DNA immunization combined with scFv phage display identifies antagonistic GCCR specific antibodies and reveals new epitopes on the small extracellular loops. <i>MAbs</i> , 2016, 8, 1126-1135.	5.2	25
190	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. <i>Annual Review of Immunology</i> , 2016, 34, 635-659.	21.8	500
191	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496.	14.3	335
192	Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16068.	4.1	48
193	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. <i>Retrovirology</i> , 2016, 13, 62.	2.0	45
194	Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities. <i>ChemMedChem</i> , 2016, 11, 357-362.	3.2	11
195	Combining somatic mutations present in different <i>in vivo</i> affinity-matured antibodies isolated from immunized <i>Lama glama</i> yields ultra-potent antibody therapeutics. <i>Protein Engineering, Design and Selection</i> , 2016, 29, 123-133.	2.1	10
196	Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites. <i>Journal of Virology</i> , 2016, 90, 829-841.	3.4	21
197	HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution. <i>Virus Research</i> , 2016, 218, 57-70.	2.2	14
198	Identification and specificity of broadly neutralizing antibodies against HIV.	6.0	198
199	Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting. <i>Biochemistry</i> , 2017, 56, 957-970.	2.5	27
200	Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures. <i>Retrovirology</i> , 2017, 14, 6.	2.0	10
201	Progress toward active or passive HIV-1 vaccination. <i>Journal of Experimental Medicine</i> , 2017, 214, 3-16.	8.5	118
202	Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies. <i>Virology</i> , 2017, 501, 12-24.	2.4	9
203	A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3. <i>MAbs</i> , 2018, 10, 636-650.	5.2	16

#	ARTICLE	IF	CITATIONS
204	New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. Annual Review of Medicine, 2018, 69, 409-419.	12.2	28
205	Single molecule fate of HIV-1 envelope reveals late-stage viral lattice incorporation. Nature Communications, 2018, 9, 1861.	12.8	35
206	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. Journal of Experimental Medicine, 2019, 216, 2331-2347.	8.5	13
207	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. MBio, 2019, 10, .	4.1	17
208	Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126. Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	11
209	Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design. Current Topics in Microbiology and Immunology, 2020, 428, 31-87.	1.1	0
210	SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles. Journal of Virology, 2020, 94, .	3.4	15
211	Vaccination Strategies Against Highly Variable Pathogens. Current Topics in Microbiology and Immunology, 2020, , .	1.1	1
212	Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail. Journal of Virology, 2020, 94, .	3.4	9
213	Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations. Polymers, 2020, 12, 2392.	4.5	0
214	CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection. Frontiers in Immunology, 2021, 12, 708355.	4.8	5
215	B-Cell Sites in the HIV Glycoproteins. , 1996, , 57-78.		1
216	Antibodies from Phage Display Libraries as Immunochemical Reagents. Methods in Molecular Biology, 1998, 80, 475-500.	0.9	13
217	The Combinatorial Approach to Human Antibodies. Handbook of Experimental Pharmacology, 1994, , 243-266.	1.8	1
218	Antibodies from Escherichia coli. Handbook of Experimental Pharmacology, 1994, , 269-315.	1.8	8
219	Production of Human Monoclonal Antibodies Against Rabies Virus. Current Topics in Microbiology and Immunology, 1994, 187, 195-205.	1.1	10
220	Intrabodies as Antiviral Agents. Current Topics in Microbiology and Immunology, 2001, 260, 247-270.	1.1	21
221	Mechanisms of Virus Neutralization by Antibody. Current Topics in Microbiology and Immunology, 2001, 260, 87-108.	1.1	46

#	ARTICLE	IF	CITATIONS
222	Designing Intrabodies: Structural Features and the Use of Intracellular Trafficking Signals. , 1998, , 1-22.		1
223	Building synthetic antibodies as adhesive ligands for integrins. Journal of Biological Chemistry, 1994, 269, 32788-32795.	3.4	46
224	Effect of Natural HIV-1 Envelope V1-V2 Sequence Diversity on the Binding of V3-Specific and Non-V3-Specific Antibodies. Journal of Acquired Immune Deficiency Syndromes, 1997, 16, 69-73.	0.3	15
225	Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists. Journal of General Virology, 2016, 97, 2427-2440.	2.9	11
226	Human Fab fragments specific for the Haemophilus influenzae b polysaccharide isolated from a bacteriophage combinatorial library use variable region gene combinations and express an idiotype that mirrors in vivo expression. Infection and Immunity, 1997, 65, 261-266.	2.2	36
227	A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. Journal of Virology, 1994, 68, 4636-4642.	3.4	70
228	Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of Virology, 1994, 68, 4821-4828.	3.4	441
229	Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles. Journal of Virology, 1996, 70, 6557-6562.	3.4	6
230	In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope. Journal of Virology, 1996, 70, 9046-9050.	3.4	51
231	Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. Journal of Virology, 1996, 70, 753-762.	3.4	77
232	Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. Journal of Virology, 1996, 70, 5236-5245.	3.4	32
233	Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. Journal of Virology, 1997, 71, 8289-8298.	3.4	58
234	Challenges in Designing HIV Env Immunogens for Developing a Vaccine. , 2008, , 327-379.		1
235	HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells. Journal of Clinical Investigation, 2017, 127, 4352-4364.	8.2	17
236	Bioinformatic Prediction of Interaction between Flavonoids of Propolis of Honey Bee and Envelope Glycoprotein GP120. International Journal of Scientific Research in Environmental Sciences, 2014, 2, 85-93.	0.1	3
237	Anti-HIV-1 Response Elicited in Rabbits by Anti-Idiotypic Monoclonal Antibodies Mimicking the CD4-Binding Site. PLoS ONE, 2008, 3, e3423.	2.5	21
238	Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes. PLoS Pathogens, 2020, 16, e1009185.	4.7	14
240	HIV-1 Vaccine Strategies Utilizing Viral Vectors Including Antigen- Displayed Inoviral Vectors. Current HIV Research, 2014, 11, 610-622.	0.5	2

#	ARTICLE	IF	CITATIONS
241	High affinity mouse-human chimeric Fab against Hepatitis B surface antigen. World Journal of Gastroenterology, 2005, 11, 7569.	3.3	5
242	Bacterial expression of a neutralizing mouse monoclonal antibody Fab fragment to a 150-kilodalton surface antigen of Entamoeba histolytica.. American Journal of Tropical Medicine and Hygiene, 1999, 60, 35-40.	1.4	15
243	Broadly neutralizing antibodies for the treatment of HIV infection. HIV Infection and Immunosuppressive Disorders, 2021, 13, 81-95.	0.3	1
246	Genetically Engineered Antibodies. , 1993, , 625-639.		1
247	Recombinant Therapeutic Human Monoclonal Antibodies. Handbook of Experimental Pharmacology, 1994, , 23-48.	1.8	0
248	Phage-Display Libraries. Springer Protocols, 1998, , 581-594.	0.3	0
249	Engineering Antibody Molecules. , 1998, , 123-148.		0
260	Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO Journal, 1994, 13, 3245-60.	7.8	219
261	Engineering panâ€“HIV-1 neutralization potency through multispecific antibody avidity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	11
262	Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds. Bioorganic and Medicinal Chemistry Letters, 2022, 69, 128768.	2.2	1
263	Endocytosed HIV-1 Envelope Glycoprotein Traffics to Rab14 ⁺ Late Endosomes and Lysosomes to Regulate Surface Levels in T-Cell Lines. Journal of Virology, 0, , .	3.4	9
265	Adjuvants influence the maturation of VRC01-like antibodies during immunization. IScience, 2022, 25, 105473.	4.1	0
266	Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.. Journal of Immunology, 1995, 154, 893-906.	0.8	82
269	Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells. Journal of Virology, 2023, 97, .	3.4	0
270	Implications of the 375W mutation for HIV-1 tropism and vaccine development. Journal of Virology, 2024, 98, .	3.4	0